Conference Coverage: ASCO GI 2025 Highlights

Expert perspectives and strategic insights on the latest therapeutic developments in GI cancer treatment from the 2025 ASCO GI Cancers Symposium, and implications on individualized clinical decision-making

January 25, 2025
Purchase Report

FACULTY CHAIR

Tanios Bekaii-Saab, MD, FACP

Mayo Clinic, Phoenix, AZ, USA

Faculty Members

Kristen Ciombor, MD
Vanderbilt University, Nashville, TN, USA

John Strickler, MD
Duke University, Durham, NC, USA

Scott Kopetz, MD, PhD
MD Anderson Cancer Center, Houston, TX, USA

Nilofer Azad, MD
Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, USA

Thierry André, MD
Sorbonne Université, Paris, France

Sample Report

Start discovering the insights

View Report

KEY TAKEAWAYS AND STRATEGIC INSIGHTS

  • Colorectal Cancer – Systemic Therapy; Initial Data Release
  • Colorectal Cancer – Biomarkers
  • Hepatocellular Carcinoma
  • Esophageal Cancers; Insights on Patient Selection for Tislelizumab From Subgroup Analyses
  • Gastric and Gastroesophageal Junction (GEJ) Cancers; Insights on Patient Selection From Subgroup Analyses
  • Pancreatic Cancer and Biliary Tract Cancer

Purchase Report

Thank you for your interest in our insights.

Complete the form below to receive additional information.